Annual Accounts Payable
$646.80 K
-$504.40 K-43.82%
31 December 2023
Summary:
Inhibikase Therapeutics annual accounts payable is currently $646.80 thousand, with the most recent change of -$504.40 thousand (-43.82%) on 31 December 2023. During the last 3 years, it has fallen by -$1.07 million (-62.41%). IKT annual accounts payable is now -62.41% below its all-time high of $1.72 million, reached on 31 December 2020.IKT Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Payable
$2.53 M
+$1.19 M+88.68%
30 September 2024
Summary:
Inhibikase Therapeutics quarterly accounts payable is currently $2.53 million, with the most recent change of +$1.19 million (+88.68%) on 30 September 2024. Over the past year, it has increased by +$1.79 million (+244.30%). IKT quarterly accounts payable is now -23.51% below its all-time high of $3.31 million, reached on 30 September 2020.IKT Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
IKT Accounts Payable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -43.8% | +244.3% |
| 3 y3 years | -62.4% | +356.7% |
| 5 y5 years | -32.2% | - |
IKT Accounts Payable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -62.4% | at low | at high | +356.7% |
| 5 y | 5 years | -62.4% | at low | -23.5% | +356.7% |
| alltime | all time | -62.4% | at low | -23.5% | +356.7% |
Inhibikase Therapeutics Accounts Payable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $2.53 M(+88.7%) |
| June 2024 | - | $1.34 M(+3.6%) |
| Mar 2024 | - | $1.29 M(+100.0%) |
| Dec 2023 | $646.80 K(-43.8%) | $646.80 K(-12.0%) |
| Sept 2023 | - | $734.60 K(-2.6%) |
| June 2023 | - | $754.10 K(-21.4%) |
| Mar 2023 | - | $959.10 K(-16.7%) |
| Dec 2022 | $1.15 M | $1.15 M(+47.4%) |
| Sept 2022 | - | $781.20 K(-9.2%) |
| June 2022 | - | $860.40 K(+6.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2022 | - | $806.20 K(-26.0%) |
| Dec 2021 | $1.09 M(-36.7%) | $1.09 M(+96.8%) |
| Sept 2021 | - | $553.80 K(-38.3%) |
| June 2021 | - | $897.20 K(+25.5%) |
| Mar 2021 | - | $715.00 K(-58.4%) |
| Dec 2020 | $1.72 M(+71.8%) | $1.72 M(-48.0%) |
| Sept 2020 | - | $3.31 M(+202.2%) |
| June 2020 | - | $1.09 M(+45.2%) |
| Mar 2020 | - | $753.50 K(-24.8%) |
| Dec 2019 | $1.00 M(+5.0%) | $1.00 M |
| Dec 2018 | $954.20 K | - |
FAQ
- What is Inhibikase Therapeutics annual accounts payable?
- What is the all time high annual accounts payable for Inhibikase Therapeutics?
- What is Inhibikase Therapeutics annual accounts payable year-on-year change?
- What is Inhibikase Therapeutics quarterly accounts payable?
- What is the all time high quarterly accounts payable for Inhibikase Therapeutics?
- What is Inhibikase Therapeutics quarterly accounts payable year-on-year change?
What is Inhibikase Therapeutics annual accounts payable?
The current annual accounts payable of IKT is $646.80 K
What is the all time high annual accounts payable for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high annual accounts payable is $1.72 M
What is Inhibikase Therapeutics annual accounts payable year-on-year change?
Over the past year, IKT annual accounts payable has changed by -$504.40 K (-43.82%)
What is Inhibikase Therapeutics quarterly accounts payable?
The current quarterly accounts payable of IKT is $2.53 M
What is the all time high quarterly accounts payable for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high quarterly accounts payable is $3.31 M
What is Inhibikase Therapeutics quarterly accounts payable year-on-year change?
Over the past year, IKT quarterly accounts payable has changed by +$1.79 M (+244.30%)